Pharma News, 2024

As part of the deal, which could be worth $3.5bn, BMS will gain developmental support and therapeutic reagents from Prime Medicine. Bristol Myers Squibb (BMS) has agreed to a research and lice...

Sepsis represents a significant global burden. The National Preclinical Sepsis Platform (NPSP) is leading vital sepsis research, informing policy, driving innovation, and ultimately saving liv...

Fresenius Kabi and Formycon have won US Food and Drug Administration (FDA) approval for Otulfi (ustekinumab-aauz), a biosimilar that references Johnson & Johnson’s (J&J) blockbuster infl...

The WHO has raised the alarm for a new worrying epidemic. This time, the focus of international concerns is the Marburg virus, which in recent days has hit Rwanda hard, where 26 cases of infection and...

AlzeCure Pharma AB (publ) announced that an abstract with preclinical data on NeuroRestore ACD856 demonstrating its anti-inflammatory and immunomodulatory effects has been accepted for present...

A widely available and inexpensive antidepressant drug may soon save lives from an altogether different kind of disease.

A federal judge has dismissed a $6.4 billion lawsuit brought by Celgene shareholders against Bristol Myers Squibb for the second time in 19 months, ruling that the filing was brought by an "impro...

Centessa Pharmaceuticals has presented preclinical data on ORX142, an investigational orexin receptor 2 (OX2R) agonist, during the 27th Congress of the European Sleep Research Society. ORX142 ...

Valerio Therapeutics, a developer of DNA Decoy therapeutics, has announced its acquisition of Emglev Therapeutics, a company specialising in single-domain antibody-based therapeutics. This strategic m...

After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials tes...

The FDA has approved Aqneursa as an oral treatment for neurological symptoms associated with Niemann-Pick disease type C, a rare genetic disease, in adults and children weighing at least 15 kg, accord...

Biomea Fusion’s stock is on the up after the company plans to resume two clinical trials evaluating its therapy for type 1 (T1D) and 2 diabetes (T2D) after the US Food and Drug Admin...